CTOs on the Move

Surrozen

www.surrozen.com

 
Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.surrozen.com
  • 171 Oyster Point Blvd Suite 400
    South San Francisco, CA USA 94080
  • Phone: 650.475.2820

Executives

Name Title Contact Details

Funding

Surrozen raised $33M on 02/15/2017
Surrozen raised $50M on 03/15/2019
Surrozen raised $50M on 06/19/2020

Similar Companies

Pharma Connections Worldwide

Pharma Connections Worldwide is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioMx

BioMx is a South Amboy, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Applied Molecular Transport

Applied Molecular Therapeutics (AMT), a public biopharmaceutical company based in South San Francisco, California, is committed to developing novel, oral biological therapeutics to treat severe autoimmune, metabolic and inflammatory diseases. AMT is leveraging its propriety technology platforms to create gastrointestinal (GI)-select therapeutics that harness naturally occurring transport and targeting mechanisms to cross the protective barrier of the intestinal epithelium (IE). Once across the IE, the therapeutics gain privileged access to the immune cell-rich environment of the GI tissue as well as the hepatic portal system and downstream systemic circulation. With this privileged access, AMT`s goal is to develop transformative new oral therapeutic treatment options that offer patients greater efficacy and tolerability than available with today`s therapeutics. AMT has a robust pipeline of oral biologic product opportunities, including AMT-101 which is currently in Phase 1b clinical development for the treatment of adults with ulcerative colitis (UC). AMT-101 is a novel, gut-selective, investigational oral biologic fusion protein of interleukin 10 (IL-10), an anti-inflammatory cytokine. Derived from AMT`s proprietary platforms, AMT-101 is engineered to cross the selective barrier of the IE and enhance localized IL-10 directly within the immune-cell rich environment of GI tissue where up to 75 percent of immune cells reside. This direct targeting of the immune system creates the potential for AMT-101 to address, at its point of origin, the immune dysregulation that gives rise to UC and other inflammatory bowel diseases, and restore immune homeostasis with minimal systemic exposure and potentially fewer adverse events compared to systemic administration of IL-10. AMT has amassed a broad global IP portfolio surrounding its multiple technology platforms and therapeutic programs.

IntegenX

IntegenX is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Steven Rosenstein Associates

Steven Rosenstein Associates is a Skokie, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.